Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock

Everolimus (EV), a rapamycin analogue mTOR inhibitor, is used in the clinic to treat Estrogen positive (ER(+)) breast cancer in order to avoid the resistance to hormonotherapy. Here, we investigated whether EV efficacy varied according to administration timing by using the ER(+) breast cancer cell l...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cell Cycle
मुख्य लेखकों: Zhang, Yuan, Giacchetti, Sylvie, Parouchev, Alexandre, Hadadi, Eva, Li, Xiaomei, Dallmann, Robert, Xandri-Monje, Helena, Portier, Lucie, Adam, René, Lévi, Françis, Dulong, Sandrine, Chang, Yunhua
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Taylor & Francis 2018
विषय:
Reports
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815427/
https://ncbi.nlm.nih.gov/pubmed/29099263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1387695
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन